FLT1 and neoplasm: In addition to CAR-T cells targeted against PSMA, they have also been targeted against the tumour blood vessel markers VEGFR-2 [175], VEGFR1 [176], TEM8 [177] and fibronectin splice variant EIIIB [165,178].